Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 2/20 | 0.61 |
| ▸ | RAB9A | P51151 | 2/20 | 0.61 |
| ▸ | CASP3 | P42574 | 1/20 | 0.50 |
| ▸ | POLB | P06746 | 1/20 | 0.50 |
| ▸ | MGLL | Q99685 | 3/20 | 0.48 |
| ▸ | MAOB | P27338 | 1/20 | 0.48 |
| ▸ | MEN1 | O00255 | 1/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.48 |
| ▸ | ELANE | P08246 | 1/20 | 0.47 |
| ▸ | PLAU | P00749 | 1/20 | 0.47 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.47 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.46 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.46 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.46 |
| ▸ | LMNA | P02545 | 2/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2233522 | 0.83 | NPC1 (0.69) | NPC1RAB9ACASP3POLBMGLL | |
| SCHEMBL5242603 | 0.81 | NPC1 (0.56) | NPC1RAB9ACASP3POLBMGLL | |
| SCHEMBL6190439 | 0.81 | NPC1 (0.66) | NPC1RAB9ACASP3POLBMGLL | |
| SCHEMBL22497537 | 0.80 | TRPV1 (0.58) | NPC1RAB9APOLBMGLLMEN1 | |
| SCHEMBL10874779 | 0.79 | NPC1 (0.68) | NPC1RAB9APOLBMEN1KMT2A | |
| SCHEMBL5241284 | 0.78 | RAB9A (0.55) | NPC1RAB9ACASP3MGLLMEN1 | |
| SCHEMBL16193532 | 0.77 | NPC1 (0.69) | NPC1RAB9ACASP3POLBMGLL | |
| SCHEMBL30522295 | 0.77 | NPC1 (0.69) | NPC1RAB9ACASP3POLBMGLL | |
| SCHEMBL22497489 | 0.77 | KDM4E (0.61) | NPC1RAB9ACASP3POLBMGLL | |
| SCHEMBL6718898 | 0.77 | POLB (0.66) | NPC1RAB9APOLBMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040087491-A1 | Electrophilic ketones for the treatment of herpesvirus infections | FLYNN DANIEL L (US) | 2004-05-06 | — | — | US | claimed |
| US-20030119721-A1 | Electrophilic ketones for the treatment of herpesvirus infections | G. D. SEARLE & CO., CORPORATE PATENT DEPARTMENT | 2003-06-26 | — | — | US | claimed |
| EP-0888322-B1 | ELECTROPHILIC KETONES FOR THE TREATMENT OF HERPESVIRUS INFECTIONS | SEARLE & CO (US) | 2002-09-18 | — | — | EP | claimed |
| US-20040087491-A1 | Electrophilic ketones for the treatment of herpesvirus infections | FLYNN DANIEL L (US) | 2004-05-06 | — | — | US | disclosed |
| US-6673788-B2 | CONTAINING 2,2,2-TRIFLUORO-1-OXOETHYL GROUPS | G. D. SEARLE & CO. | 2004-01-06 | — | — | US | disclosed |
| US-6673784-B1 | HALOSUBSTITUTED ACETOPHENONES AS SELECTIVE HERPESVIRUS PROTEASE INHIBITORS | G. D. SEARLE & CO. | 2004-01-06 | — | — | US | disclosed |
| US-20030119721-A1 | Electrophilic ketones for the treatment of herpesvirus infections | G. D. SEARLE & CO., CORPORATE PATENT DEPARTMENT | 2003-06-26 | — | — | US | disclosed |
| EP-0888322-B1 | ELECTROPHILIC KETONES FOR THE TREATMENT OF HERPESVIRUS INFECTIONS | SEARLE & CO (US) | 2002-09-18 | — | — | EP | disclosed |
| EP-0888322-A2 | ELECTROPHILIC KETONES FOR THE TREATMENT OF HERPESVIRUS INFECTIONS | G.D. SEARLE & CO. (US) | 1999-01-07 | — | — | EP | disclosed |
| WO-1997034566-A2 | ELECTROPHILIC KETONES FOR THE TREATMENT OF HERPESVIRUS INFECTIONS | G.D. SEARLE & CO. (US) | 1997-09-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040087491-A1 | Electrophilic ketones for the treatment of herpesvirus infections | KHK, HCK, PBK | NPC1 1523/4885RAB9A 1684/4885CASP3 2907/4885 |
| US-20030119721-A1 | Electrophilic ketones for the treatment of herpesvirus infections | KHK, HCK, PBK | NPC1 1523/4885RAB9A 1684/4885CASP3 2907/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.